Sanofi (France)
NEWS
Sanofi will drop its IL-2 candidate, citing a lack of efficacy in the early stages of data collection, the company announced in its Q3 report Friday.
BioMed X and Sanofi have inked an R&D collaboration to use digital data and artificial intelligence to predict the efficacy of first-in-class drug candidates using virtual patient populations.
Novartis, GlaxoSmithKline and Sanofi have announced plans for significant cutbacks and changes in their labor force overseas for financial, operational and logistical reasons.
Data from an ongoing Phase III trial showed Sanofi/Regeneron’s Dupixent can induce histological disease remission in young EoE patients aged 1–11.
Sanofi announced FDA approval of Xenpozyme for adult and pediatric patients with the rare genetic disease acid sphingomyelinase deficiency, often referred to as Niemann-Pick disease.
Atomwise inked a strategic research-and-development deal with Sanofi to use the AtomNet platform to identify and research up to five drug targets.
All other ongoing and pending studies of Sanofi’s amcenestrant, including the early-stage breast cancer trial AMEERA-6, will also be discontinued.
The real positive drivers were Eylea and Dupixent. Eylea climbed 14% to $1.62 billion, while Dupixent sales jumped almost 40% to $2.09 billion for the second quarter.
The end of July is busy for the FDA, with Coherus, Sanofi, Acadia, Myovant and Pfizer having PDUFA dates filling the calendar. Here’s a look.
JOBS
IN THE PRESS